FGFR4.28HTM.BBz showed similar in vitro tumor-killing ability and cytokine production as the original FGFR4.8HTM.BBz CAR T-cells (Fig. 1B, C), but exhibited enhanced in vivo antitumor activity (Fig S1, B to E; Fig. 1F). The gene discussed is FGFR4; the disease is neoplasm.